Contraindications for Bisphosphonate Therapy in Osteoporosis

Absolute Contraindications

The National Comprehensive Cancer Network recommends that bisphosphonates should not be prescribed to patients with esophageal emptying disorders, inability to sit upright, creatinine clearance less than 30 mL/min, uncorrected vitamin D deficiency, or those requiring dental procedures 1, 2, 3
Renal impairment is a contraindication for intravenous bisphosphonates in patients with creatinine clearance less than 30 mL/min due to risk of increased serum creatinine and potential acute renal failure 1, 2
Esophageal disorders, such as esophageal emptying disorders or inability to sit upright for at least 30 minutes, are a contraindication for oral bisphosphonates due to high risk of pill esophagitis 1, 3
Uncorrected hypocalcemia or vitamin D deficiency is a contraindication for bisphosphonate therapy, especially intravenous formulations, as hypocalcemia has been reported in patients with unrecognized vitamin D deficiency 1

The National Comprehensive Cancer Network recommends that patients requiring invasive dental procedures should delay starting bisphosphonate therapy if possible 1, 3
Poor oral hygiene is a risk factor for osteonecrosis of the jaw (ONJ) in patients on bisphosphonate therapy 1
Recent dental extraction is a risk factor for ONJ in patients on bisphosphonate therapy 1

For patients with moderate renal impairment (creatinine clearance between 30-60 mL/min), dose adjustments may be required for zoledronic acid 4
The American College of Clinical Oncology recommends that bisphosphonates are not recommended for asymptomatic myeloma or monoclonal gammopathy of undetermined significance (MGUS) unless osteopenia/osteoporosis is present 4
The American College of Clinical Oncology recommends that starting bisphosphonates is not recommended for solitary plasmacytoma 4

Bisphosphonates should be avoided in pregnant women or women planning pregnancy due to potential fetal harm 5

For patients with renal impairment, oral bisphosphonates may be considered as an alternative treatment 1
For patients who cannot tolerate oral formulations, intravenous bisphosphonates may be considered if renal function permits 1
For patients with severe renal impairment, denosumab or raloxifene may be considered as alternative treatments 5

Before initiating therapy, assess renal function with creatinine clearance, check vitamin D status and correct deficiency, perform dental examination and complete necessary dental procedures, and optimize calcium intake 1, 3
During therapy, monitor renal function and serum calcium regularly, and ensure adequate calcium and vitamin D supplementation 1, 3

Osteonecrosis of the jaw risk is a rare but potential side effect of bisphosphonate therapy, and patients should be advised against unnecessary invasive oral surgery while on bisphosphonate therapy 1